Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 7
1981 13
1982 4
1983 8
1984 5
1985 11
1986 10
1987 13
1988 11
1989 13
1990 10
1991 15
1992 16
1993 22
1994 44
1995 34
1996 33
1997 33
1998 43
1999 53
2000 53
2001 56
2002 86
2003 122
2004 133
2005 157
2006 178
2007 184
2008 287
2009 275
2010 361
2011 467
2012 544
2013 655
2014 860
2015 890
2016 923
2017 1135
2018 1208
2019 1377
2020 1602
2021 1815
2022 2048
2023 1958
2024 1955
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,723 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: xu b. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: xu b. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Among authors: xu b. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
Acupuncture for cancer pain: an evidence-based clinical practice guideline.
Ge L, Wang Q, He Y, Wu D, Zhou Q, Xu N, Yang K, Chen Y, Zhang AL, Hua H, Huang J, Hui KK, Liang F, Wang L, Xu B, Yang Y, Zhang W, Zhao B, Zhu B, Guo X, Xue CC, Zhang H; International Trustworthy traditional Chinese Medicine Recommendations (TCM Recs) Working Group. Ge L, et al. Among authors: xu b. Chin Med. 2022 Jan 5;17(1):8. doi: 10.1186/s13020-021-00558-4. Chin Med. 2022. PMID: 34983587 Free PMC article. Review.
Rapid DNA unwinding accelerates genome editing by engineered CRISPR-Cas9.
Eggers AR, Chen K, Soczek KM, Tuck OT, Doherty EE, Xu B, Trinidad MI, Thornton BW, Yoon PH, Doudna JA. Eggers AR, et al. Among authors: xu b. Cell. 2024 Jun 20;187(13):3249-3261.e14. doi: 10.1016/j.cell.2024.04.031. Epub 2024 May 22. Cell. 2024. PMID: 38781968 Free article.
A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement.
Chen Y, Yang K, Marušic A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ES, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. Chen Y, et al. Among authors: xu b. Ann Intern Med. 2017 Jan 17;166(2):128-132. doi: 10.7326/M16-1565. Epub 2016 Nov 22. Ann Intern Med. 2017. PMID: 27893062
Patient-derived organoids in precision cancer medicine.
Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, Xu B, Zhang Q, Li Z, Seashore-Ludlow B, Yang Y, Si L, Lundqvist A. Tong L, et al. Among authors: xu b. Med. 2024 Nov 8;5(11):1351-1377. doi: 10.1016/j.medj.2024.08.010. Epub 2024 Sep 27. Med. 2024. PMID: 39341206 Free article. Review.
An atlas of genetic effects on cellular composition of the tumor microenvironment.
Cai Y, Lu Z, Chen C, Zhu Y, Chen Z, Wu Z, Peng J, Zhu X, Liu Z, Li B, Zhang M, Huang J, Li Y, Liu Y, Ma Q, He C, Chen S, Tian W, Fan L, Ning C, Geng H, Xu B, Li H, Zhu X, Fang J, Wang X, Zhang S, Jin M, Huang C, Yang X, Tian J, Miao X. Cai Y, et al. Among authors: xu b. Nat Immunol. 2024 Oct;25(10):1959-1975. doi: 10.1038/s41590-024-01945-3. Epub 2024 Sep 2. Nat Immunol. 2024. PMID: 39223350
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.
Xu B, Dong SY, Bai XL, Song TQ, Zhang BH, Zhou LD, Chen YJ, Zeng ZM, Wang K, Zhao HT, Lu N, Zhang W, Li XB, Zheng SS, Long G, Yang YC, Huang HS, Huang LQ, Wang YC, Liang F, Zhu XD, Huang C, Shen YH, Zhou J, Zeng MS, Fan J, Rao SX, Sun HC. Xu B, et al. Liver Cancer. 2022 Nov 28;12(3):262-276. doi: 10.1159/000528034. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601982 Free PMC article.
17,723 results
You have reached the last available page of results. Please see the User Guide for more information.